Epigenetic therapy and dermatologic disease: moving beyond CTCL

References

• Rodríguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med. 2011;17:330–339.
   PubMed Web of Science ®Google Scholar
• Berger SL, Kouzarides T, Shiekhattar R, et al. An operational definition of epigenetics. Genes Dev. 2009;23:781–783.
   PubMed Web of Science ®Google Scholar
• Handy DE, Castro R, Loscalzo J. Epigenetic modifications: basic mechanisms and role in cardiovascular disease. Circulation. 2011;123:2145–2156.
   PubMed Web of Science ®Google Scholar
• Robertson KD. DNA methylation and human disease. Nat Rev Genet. 2005;6:597–610.
   PubMed Web of Science ®Google Scholar
• Kouzarides T. Chromatin modifications and their function. Cell. 2007;128:693–705.
   PubMed Web of Science ®Google Scholar
• Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell. 2007;28:669–681.
   Google Scholar
• Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–355.
   PubMed Web of Science ®Google Scholar
• Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012 150:12–27.
   PubMed Web of Science ®Google Scholar
• Buenrostro JD, Wu B, Litzenburger UM, et al. Single-cell chromatin accessibility reveals principles of regulatory variation. Nature. 2015;523:486–490.
   PubMed Web of Science ®Google Scholar
• Jones PA, Issa JP, Baylin S. Targeting the cancer epigenome for therapy. Nat Rev Genet. 2016;17:630–641.
   PubMed Web of Science ®Google Scholar
• Shah MY, Ferrajoli A, Sood AK, et al. microRNA therapeutics in cancer - an emerging concept. EBioMedicine. 2016;12:34–42.
   PubMed Web of Science ®Google Scholar
• New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol. 2012;6:637–656.
   PubMed Web of Science ®Google Scholar
• Chiappinelli KB, Zahnow CA, Ahuja N, et al. Combining epigenetic and immunotherapy to combat cancer. Cancer Res. 2016;76:1683–1689.
   PubMed Web of Science ®Google Scholar
• Clements EG, Mohammad HP, Leadem BR, et al. DNMT1 modulates gene expression without its catalytic activity partially through its interactions with histone-modifying enzymes. Nucleic Acids Res. 2012;40:4334–4346.
   PubMed Web of Science ®Google Scholar
• Gros C, Fahy J, Halby L, et al. DNA methylation inhibitors in cancer: recent and future approaches. Biochimie. 2012;94:2280–96.
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Horwitz SM. Targeting histone deacetylases in T-cell lymphoma. Leuk Lymphoma. 2017;58:1306–1319.
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Robey R, Sandor V, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood. 2001;98:2865–2868.
   PubMed Web of Science ®Google Scholar
• Héninger E, Krueger TE, Lang JM. Augmenting antitumor immune responses with epigenetic modifying agents. Front Immunol. 2015;6:29.
   PubMed Web of Science ®Google Scholar
• West AC, Mattarollo SR, Shortt J, et al. An intact immune system is required for the anticancer activities of histone deacetylase inhibitors. Cancer Res. 2013;73:7265–7276.
   PubMed Web of Science ®Google Scholar
• Qu K, Zaba LC, Satpathy AT, et al. Chromatin accessibility landscape of cutaneous T cell lymphoma and dynamic response to HDAC inhibitors. Cancer Cell. 2017;32:27–41.e4.
   PubMed Web of Science ®Google Scholar
• Sarkar D, Leung EY, Baguley BC, et al. Epigenetic regulation in human melanoma: past and future. Epigenetics. 2015;10:103–121.
   PubMed Web of Science ®Google Scholar
• Sigalotti L, Covre A, Fratta E, et al. Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. J Transl Med. 2010;8:56.
   PubMed Web of Science ®Google Scholar
• Flørenes VA, Skrede M, Jørgensen K, et al. Deacetylase inhibition in malignant melanomas: impact on cell cycle regulation and survival. Melanoma Res. 2004;14:173–181.
   PubMed Web of Science ®Google Scholar
• Zhang XD, Gillespie SK, Borrow JM, et al. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol Cancer Ther. 2004;3:425–435.
   PubMed Web of Science ®Google Scholar
• Haas NB, Quirt I, Hotte S, et al. Phase II trial of vorinostat in advanced melanoma. Invest New Drugs. 2014;32:526–534.
   PubMed Web of Science ®Google Scholar
• Millward M, Price T, Townsend A, et al. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest New Drugs. 2012;30:2303–2317.
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Beumer JH, Tarhini AA, et al. Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. Ann Oncol. 2013;24:1112–1119.
   PubMed Web of Science ®Google Scholar
• Tsai HC, Li H, Van Neste L, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 2012;21:430–446.
   PubMed Web of Science ®Google Scholar
• Xia C, Leon-Ferre R, Laux D, et al. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide). Cancer Chemother Pharmacol. 2014;74:691–697.
   PubMed Web of Science ®Google Scholar
• Chiappinelli KB, Strissel PL, Desrichard A, et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell. 2015;162:974–986.
   PubMed Web of Science ®Google Scholar
• Laugesen A, Helin K. Chromatin repressive complexes in stem cells, development, and cancer. Cell Stem Cell. 2014;14:735–751.
   PubMed Web of Science ®Google Scholar
• Kalin JH, Wu M, Gomez AV, et al. Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Nat Commun. 2018;9:53.
   PubMed Web of Science ®Google Scholar
• Wilms C, Kroeger CM, Hainzl AV, et al. MYSM1/2A-DUB is an epigenetic regulator in human melanoma and contributes to tumor cell growth. Oncotarget. 2017;8:67287–67299.
   PubMedGoogle Scholar
• Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386:983–994.
   PubMed Web of Science ®Google Scholar
• Generali E, Ceribelli A, Stazi MA, et al. Lessons learned from twins in autoimmune and chronic inflammatory diseases. J Autoimmun. 2017;83:51–61.
   PubMed Web of Science ®Google Scholar
• Trowbridge RM, Pittelkow MR. Epigenetics in the pathogenesis and pathophysiology of psoriasis vulgaris. J Drugs Dermatol. 2014;13:111–118.
   PubMed Web of Science ®Google Scholar
• McLaughlin F, La Thangue NB. Histone deacetylase inhibitors in psoriasis therapy. CDTIA. 2004;3:213–219.
   Google Scholar
• Leoni F, Zaliani A, Bertolini G, et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci U S A. 2002;99:2995–3000.
   PubMed Web of Science ®Google Scholar
• Saunders N, Dicker A, Popa C, et al. Histone deacetylase inhibitors as potential anti-skin cancer agents. Cancer Res. 1999;59:399–404.
   PubMed Web of Science ®Google Scholar
• Kwon HJ, Kim MS, Kim MJ, et al. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int J Cancer. 2002;97:290–296.
   PubMed Web of Science ®Google Scholar
• Tovar-Castillo LE, Cancino-Díaz JC, García-Vázquez F, et al. Under-expression of VHL and over-expression of HDAC-1, HIF-1alpha, LL-37, and IAP-2 in affected skin biopsies of patients with psoriasis. Int J Dermatol. 2007;46:239–246.
   PubMed Web of Science ®Google Scholar
• Ekman AK, Enerbäck C. Lack of preclinical support for the efficacy of histone deacetylase inhibitors in the treatment of psoriasis. Br J Dermatol. 2016;174:424–426.
   PubMed Web of Science ®Google Scholar
• Zhang P, Su Y, Zhao M, et al. Abnormal histone modifications in PBMCs from patients with psoriasis vulgaris. Eur J Dermatol. 2011;21:552–557.
   PubMed Web of Science ®Google Scholar
• Bovenschen HJ, van de Kerkhof PC, van Erp PE, et al. Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J Invest Dermatol. 2011;131:1853–1860.
   PubMed Web of Science ®Google Scholar
• Orecchia A, Scarponi C, Di Felice F, et al. Sirtinol treatment reduces inflammation in human dermal microvascular endothelial cells. PLoS One. 2011;6:e24307.
   PubMed Web of Science ®Google Scholar
• Xie S, Su Z, Zhang B, et al. SIRT1 Activation Ameliorates Aldara-Induced Psoriasiform Phenotype and Histology in Mice. J Invest Dermatol. 2015;135:1915–1918.
   PubMed Web of Science ®Google Scholar
• Krueger JG, Suárez-Fariñas M, Cueto I, et al. A randomized, placebo-controlled study of SRT2104, a SIRT1 activator, in patients with moderate to severe psoriasis. PLoS One. 2015;10:e0142081.
   PubMed Web of Science ®Google Scholar
• Verma D, Ekman AK, Bivik Eding C, et al. Genome-wide DNA methylation profiling identifies differential methylation in uninvolved psoriatic epidermis. J Invest Dermatol. 2017;138:1088–1093.
   PubMedGoogle Scholar
• Zhang P, Su Y, Chen H, et al. Abnormal DNA methylation in skin lesions and PBMCs of patients with psoriasis vulgaris. J Dermatol Sci. 2010;60:40–42.
   PubMed Web of Science ®Google Scholar
• Zhang P, Zhao M, Liang G, et al. Whole-genome DNA methylation in skin lesions from patients with psoriasis vulgaris. J Autoimmun. 2013;41:17–24.
   PubMed Web of Science ®Google Scholar
• Pollock RA, Abji F, Gladman DD. Epigenetics of psoriatic disease: A systematic review and critical appraisal. J Autoimmun. 2017;78:29–38.
   PubMed Web of Science ®Google Scholar
• Xia J, Zhang W. MicroRNAs in normal and psoriatic skin. Physiol Genomics. 2014;46:113–122.
   PubMed Web of Science ®Google Scholar
• Liu Q, Wu DH, Han L, et al. Roles of microRNAs in psoriasis: immunological functions and potential biomarkers. Exp Dermatol. 2017;26:359–367.
   PubMed Web of Science ®Google Scholar
• Wang MJ, Xu YY, Huang RY, et al. Role of an imbalanced miRNAs axis in pathogenesis of psoriasis: novel perspectives based on review of the literature. Oncotarget. 2017;8:5498–5507.
   PubMedGoogle Scholar
• Hawkes JE, Nguyen GH, Fujita M, et al. microRNAs in psoriasis. J Invest Dermatol. 2016;136:365–371.
   PubMed Web of Science ®Google Scholar
• Huang RY, Li L, Wang MJ, et al. An exploration of the role of micrornas in psoriasis: a systematic review of the literature. Medicine (Baltimore). 2015;94:e2030.
   PubMed Web of Science ®Google Scholar
• Long H, Yin H, Wang L, et al. The critical role of epigenetics in systemic lupus erythematosus and autoimmunity. J Autoimmun. 2016;74:118–138.
   PubMed Web of Science ®Google Scholar
• Selmi C, Lu Q, Humble MC. Heritability versus the role of the environment in autoimmunity. J Autoimmun. 2012;39:249–252.
   PubMed Web of Science ®Google Scholar
• Richardson B, Scheinbart L, Strahler J, et al. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 1990;33:1665–1673.
   PubMed Web of Science ®Google Scholar
• Lu Q, Wu A, Tesmer L, et al. Demethylation of CD40LG on the inactive X in T cells from women with lupus. J Immunol. 2007;179:6352–6358.
   PubMed Web of Science ®Google Scholar
• Richardson B. Effect of an inhibitor of DNA methylation on T cells. II. 5-Azacytidine induces self-reactivity in antigen-specific T4+ cells. Hum Immunol. 1986;17:456–470.
   PubMed Web of Science ®Google Scholar
• Lee BH, Yegnasubramanian S, Lin X, et al. Procainamide is a specific inhibitor of DNA methyltransferase 1. J Biol Chem. 2005;280:40749–40756.
   PubMed Web of Science ®Google Scholar
• Deng C, Lu Q, Zhang Z, et al. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum. 2003;48:746–756.
   PubMed Web of Science ®Google Scholar
• Pan W, Zhu S, Yuan M, et al. MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1. J Immunol. 2010;184:6773–6781.
   PubMed Web of Science ®Google Scholar
• Zhao S, Wang Y, Liang Y, et al. MicroRNA-126 regulates DNA methylation in CD4+ T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1. Arthritis Rheum. 2011;63:1376–1386.
   PubMed Web of Science ®Google Scholar
• Qin H, Zhu X, Liang J, et al. MicroRNA-29b contributes to DNA hypomethylation of CD4+ T cells in systemic lupus erythematosus by indirectly targeting DNA methyltransferase 1. J Dermatol Sci. 2013;69:61–67.
   PubMed Web of Science ®Google Scholar
• Strickland FM, Hewagama A, Wu A, et al. Diet influences expression of autoimmune-associated genes and disease severity by epigenetic mechanisms in a transgenic mouse model of lupus. Arthritis Rheum. 2013;65:1872–1881.
   PubMed Web of Science ®Google Scholar
• Garcia BA, Busby SA, Shabanowitz J, et al. Resetting the epigenetic histone code in the MRL-lpr/lpr mouse model of lupus by histone deacetylase inhibition. J Proteome Res. 2005;4:2032–2042.
   PubMed Web of Science ®Google Scholar
• Vieson MD, Gojmerac AM, Khan D, et al. Treatment with a selective histone deacetylase 6 inhibitor decreases lupus nephritis in NZB/W mice. Histol Histopathol. 2017;32:1317–1332.
   PubMed Web of Science ®Google Scholar
• Mishra N, Reilly CM, Brown DR, et al. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest. 2003;111:539–552.
   PubMed Web of Science ®Google Scholar
• Reilly CM, Mishra N, Miller JM, et al. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J Immunol. 2004;173:4171–4178.
   PubMed Web of Science ®Google Scholar
• Lei W, Luo Y, Yan K, et al. Abnormal DNA methylation in CD4+ T cells from patients with systemic lupus erythematosus, systemic sclerosis, and dermatomyositis. Scand J Rheumatol. 2009;38:369–374.
   PubMed Web of Science ®Google Scholar
• Lian X, Xiao R, Hu X, et al. DNA demethylation of CD40l in CD4+ T cells from women with systemic sclerosis: a possible explanation for female susceptibility. Arthritis Rheum. 2012;64:2338–2345.
   PubMed Web of Science ®Google Scholar
• Wang Y, Fan PS, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum. 2006;54:2271–2279.
   PubMed Web of Science ®Google Scholar
• Dees C, Schlottmann I, Funke R, et al. The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. Ann Rheum Dis. 2014;73:1232–1239.
   PubMed Web of Science ®Google Scholar
• Akhmetshina A, Palumbo K, Dees C, et al. Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat Commun. 2012;3:735.
   PubMed Web of Science ®Google Scholar
• Hemmatazad H, Rodrigues HM, Maurer B, et al. Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis. Arthritis Rheum. 2009;60:1519–1529.
   PubMed Web of Science ®Google Scholar
• Huber LC, Distler JH, Moritz F, et al. Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum. 2007;56:2755–2764.
   PubMed Web of Science ®Google Scholar
• Dawson MA, Kouzarides T, Huntly BJ. Targeting epigenetic readers in cancer. N Engl J Med. 2012;367:647–657.
   PubMed Web of Science ®Google Scholar
• Ramadoss M, Mahadevan V. Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors. Drug Discov Today. 2018;23:76–89.
   PubMed Web of Science ®Google Scholar